Loading financial data...

REGENERON PHARMACEUTICALS, INC. (REGN) Financial Statements | Global Financial Data

REGENERON PHARMACEUTICALS, INC.

REGNSEC EDGAR

Pharmaceutical Preparations(NY)CIK: 872589

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$13.1B	$12.2B	$16.1B	$8.5B	$6.6B
Cost of Goods and Services Sold	—	—	—	—	—
Research and Development Expense	$4.4B	$3.6B	$2.9B	$2.6B	$2.5B
Selling, General and Administrative Expense	$2.6B	$2.1B	$1.8B	$1.3B	$1.3B
Operating Income (Loss)	$4.0B	$4.7B	$8.9B	$3.6B	$2.2B
Interest Expense	—	—	$57.3M	$56.9M	$30.2M
Nonoperating Income (Expense)	$152.2M	$119.9M	$379.0M	$233.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$37.8B	$33.1B	$29.2B	$25.4B	$17.2B
Assets, Current	$18.7B	$19.5B	$15.9B	$14.0B	$9.8B
Cash and Cash Equivalents, at Carrying Value	$2.7B	$3.1B	$2.9B	$2.2B	$1.6B
Accounts Receivable, after Allowance for Credit Loss, Current	$6.2B	$5.7B	$5.3B	$6.0B	$4.1B
Inventory, Net	$3.1B	$2.6B	$2.4B	$2.0B	$1.9B
Liabilities	$8.4B	$7.1B	$6.6B	$6.7B	$6.1B
Liabilities, Current	$3.9B	$3.4B	$3.1B	$3.9B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$4.6B	$5.0B	$7.1B	$2.6B	$2.4B
Net Cash Provided by (Used in) Investing Activities	-$3.2B	-$3.8B	-$5.4B	-$70.6M	-$2.0B
Net Cash Provided by (Used in) Financing Activities	-$1.8B	-$1.0B	-$1.0B	-$2.0B	-$252.1M
Payments of Dividends	$0.00	—	—	—	—
Payments for Repurchase of Common Stock	$2.2B	$2.1B	$1.6B	$5.8B	$275.9M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)